Digital coach tested to keep patients on track with weight loss shots
NCT ID NCT07216651
Summary
This study tested a web-based tool called WeDosify, designed to help doctors personalize the dosing of the weight loss medication semaglutide (like Wegovy®). It involved 20 adults in the U.S. who were already starting this treatment for overweight or obesity. The main goal was to see if using the tool helped patients stay on their medication over a 3-month period and to gather feedback from both patients and doctors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amarillo Premier Research (an Objective Health Partnership)
Amarillo, Texas, 37067, United States
Conditions
Explore the condition pages connected to this study.